Galectin Therapeutics
GALT
71 hedge funds and large institutions have $26.9M invested in Galectin Therapeutics in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 13 increasing their positions, 26 reducing their positions, and 8 closing their positions.
154% more call options, than puts
Call options by funds: $648K | Put options by funds: $255K
0.17% less ownership
Funds ownership: 17.82% → 17.65% (-0.17%)
5% less funds holding
Funds holding: 75 → 71 (-4)
13% less capital invested
Capital invested by funds: $31.1M → $26.9M (-$4.18M)
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$297K |
| 2 |
Two Sigma Investments
New York
|
+$127K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$96.1K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$65.5K |
| 5 |
WAM
Wealthspire Advisors (Maryland)
Potomac,
Maryland
|
+$38.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$241K |
| 2 |
Morgan Stanley
New York
|
-$94.1K |
| 3 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
-$86K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$79.5K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$62K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citadel Advisors
Miami,
Florida
| – | -$43.1K | -15,383 | Closed |
|
77
Wolverine Trading
Chicago,
Illinois
| – | -$37.5K | -13,376 | Closed |
|
78
Group One Trading
Chicago,
Illinois
| – | -$13.5K | -4,824 | Closed |
|
GALT Hedge Fund Activity: Q3 2020 in Review
71 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2020, worth a combined $26.9M — down 13% from $31.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GALT and 4 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 13 added.
The largest buyer was Russell Investments Group, opening a new position worth an estimated $297K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $241K sold.
- 71 institutional investors held Galectin Therapeutics (GALT) as of Q3 2020, down from 75 in Q2 2020.
- Funds reported $26.9M of Galectin Therapeutics stock for Q3 2020, down 13% quarter-over-quarter.
- 4 funds opened new Galectin Therapeutics positions in Q3 2020 and 8 closed out, a net change of -4 holders.
- The largest Galectin Therapeutics buyer in Q3 2020 was Russell Investments Group, an estimated $297K added.
- The largest Galectin Therapeutics seller in Q3 2020 was D.E. Shaw & Co, an estimated $241K sold.
Based on aggregated 13F filings for Q3 2020.